The efficacy of dulaglutide, a GLP-1 receptor agonist that modulates appetite and reward-related brain areas, was compared to gliclazide, an anti-diabetic medication, in a sample of outpatients with type 2 diabetes and BED. Here, GLP1R is linked to X-linked cone dysfunction syndrome with myopia.